Marc Hedrick, M.D.
President and CEO
Plus Therapeutics
Dr. Marc Hedrick is the President and CEO at Plus Therapeutics, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.
Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.
Andrew Brenner, M.D., Ph.D.
Associate Professor of Medicine Neurology, and Neurosurgery
The University of Texas, Health Services Center at San Antonio
Dr. Brenner is a medical oncologist and tumor biologist with a focus in drug development for the management of primary brain tumors and breast neoplasms. His interests are in developing novel therapeutics for the treatment of malignancy with a focus on overcoming resistance to conventional therapeutics. This experience includes navigation of regulatory processes including IND enabling studies, authoring study protocols, coordinating multicenter studies, as well as acting as principal investigator of 14 industry and investigator-initiated Phase 1 trials since 2008. Dr. Brenner earned his bachelor’s degree in biochemistry and went on to earn his doctorate in biological science and tumor biology at The University of Texas M.D. Anderson Cancer Center – Science Park. He received his medical degree from the Texas Tech University Health Science Center and completed a residency in internal medicine at Scott and White Hospital in Lubbock, Texas. He completed his fellowship in hematology and medical oncology at the UT Health San Antonio.
Priya Kumthekar, M.D.
Associate Professor of Neurology and Hematology/Oncology & Director of the Cancer Trials Offiice
Robert H Lurie Comprehensive Cancer Center at Northwestern University
Dr. Priya Kumthekar is an Associate Professor of Neurology and Hematology/Oncology, and the Director of the Cancer Trials Office at the Robert H Lurie Comprehensive Cancer Center at Northwestern University. Kumthekar is board certified in neurology and neuro-oncology and has an MD from Northeastern Ohio Universities College of Medicine.
Dr. Kumthekar completed her residency training in neurology at Northwestern University/McGaw and her Neuro-Oncology UCNS Accredited Clinical Fellowship at the same institution.
Norman La France, M.D.
Chief Medical Officer and Senior Vice President
Plus Therapeutics
Norman LaFrance, MD is the Chief Medical Officer and Senior Vice President at Plus Therapeutics, Inc. He was previously Chief Medical Officer and Senior Vice President at Jubilant Pharma Ltd., responsible for all Pharma Medical & Regulatory Affairs activities.
Prior to Jubilant Pharma, Ltd., Dr. LaFrance served as Global Chief Medical Officer at IBA Molecular from 2010 to 2012, and as Senior Vice President, Clinical Development and Chief Medical Officer at Molecular Insight Pharmaceuticals from 2007 to 2010. Prior to industry, Dr. LaFrance practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the departments of medicine and radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is Double Board Certified with Fellowship status both in internal medicine and nuclear medicine, maintains active medical licensure in the U.S. along with active, professional society membership.
Dr. LaFrance received his Bachelor of Science and Master of Engineering degrees in nuclear engineering and science from Rensselaer Polytechnic Institute, and his medial degree from the University of Arizona, College of Medicine, Tucson.